GI Cancers Symposium

The immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy) provides durable clinical benefit in patients with previously treated DNA mismatch repair–deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (CRC). Read More ›

Regorafenib Dose-Escalation Strategy Potentially a New Standard in Metastatic Colorectal Cancer

By Wayne Kuznar

March 2018, Vol 8, No 3

A starting dose of regorafenib (Stivarga) 80 mg daily with dose escalation to 160 mg daily was better tolerated than starting at 160 mg daily, with a trend toward improved survival in the management of patients with metastatic colorectal cancer. Read More ›

Wide Variation in Follow-Up Practices After Neuroendocrine Tumor Resection

By Charles Bankhead

GI Cancers Symposium

April 2017, Vol 7, No 4

By Wayne Kuznar

GI Cancers Symposium

March 2017, Vol 7, No 3

By Wayne Kuznar

GI Cancers Symposium

March 2017, Vol 7, No 3

By Wayne Kuznar

GI Cancers Symposium